Key statistics
On Friday, Herantis Pharma Oyj (HRTIS:HEX) closed at 2.10, 75.00% above the 52 week low of 1.20 set on Apr 07, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.13 |
|---|---|
| High | 2.14 |
| Low | 2.10 |
| Bid | -- |
| Offer | -- |
| Previous close | 2.13 |
| Average volume | 42.69k |
|---|---|
| Shares outstanding | 25.93m |
| Free float | 20.14m |
| P/E (TTM) | -- |
| Market cap | 54.46m EUR |
| EPS (TTM) | -0.2417 EUR |
Data delayed at least 15 minutes, as of Feb 27 2026 17:00 GMT.
More ▼
Announcements
- Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096
- Herantis Pharma - Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease
- Herantis Pharma presents positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease
- Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease
- First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease
More ▼
